REPL
NASDAQReplimune Group Inc.
News · 26 weeks54+1150%
2025-10-262026-04-19
Mix3190d
- Insider16(52%)
- Analyst7(23%)
- Other5(16%)
- SEC Filings3(10%)
Latest news
25 items- ANALYSTReplimune downgraded by BMO Capital Markets with a new price targetBMO Capital Markets downgraded Replimune from Market Perform to Underperform and set a new price target of $1.00
- ANALYSTReplimune downgraded by Jefferies with a new price targetJefferies downgraded Replimune from Buy to Hold and set a new price target of $2.00
- ANALYSTReplimune downgraded by AnalystAnalyst downgraded Replimune from Neutral to Underweight
- ANALYSTReplimune downgraded by H.C. WainwrightH.C. Wainwright downgraded Replimune from Buy to Sell
- ANALYSTReplimune downgraded by Leerink Partners with a new price targetLeerink Partners downgraded Replimune from Outperform to Market Perform and set a new price target of $2.00
- ANALYSTReplimune downgraded by Wedbush with a new price targetWedbush downgraded Replimune from Outperform to Neutral and set a new price target of $2.00
- SECReplimune Group Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Replimune Group, Inc. (0001737953) (Filer)
- PRReplimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced MelanomaWOBURN, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the company received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) for the Company's Biologics License Application (BLA) for RP1 in combination with nivolumab for the treatment of advanced melanoma. Replimune disagrees with the FDA about whether the data set, upon which breakthrough therapy designation was awarded, is sufficient to allow this promising medicine to be made available to advanced cancer patients. In the IGNYTE trial, patients with co
- PRReplimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced MelanomaWOBURN, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the company received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) for the Company's Biologics License Application (BLA) for RP1 in combination with nivolumab for the treatment of advanced melanoma. Replimune disagrees with the FDA about whether the data set, upon which breakthrough therapy designation was awarded, is sufficient to allow this promising medicine to be made available to advanced cancer patients. In the IGNYTE trial, patients with co
- ANALYSTReplimune downgraded by Piper Sandler with a new price targetPiper Sandler downgraded Replimune from Overweight to Neutral and set a new price target of $4.00
- INSIDERSEC Form 4 filed by Baker Bros. Advisors Lp4 - Replimune Group, Inc. (0001737953) (Issuer)
- INSIDERSEC Form 4 filed by Sarchi Christopher4 - Replimune Group, Inc. (0001737953) (Issuer)
- INSIDERSEC Form 4 filed by Astley-Sparke Philip4 - Replimune Group, Inc. (0001737953) (Issuer)
- INSIDERSEC Form 4 filed by Oliger Christy J.4 - Replimune Group, Inc. (0001737953) (Issuer)
- INSIDERSEC Form 4 filed by Xynos Konstantinos4 - Replimune Group, Inc. (0001737953) (Issuer)
- INSIDERSEC Form 4 filed by Balachandran Madhavan4 - Replimune Group, Inc. (0001737953) (Issuer)
- INSIDERSEC Form 4 filed by Schwendenman Andrew4 - Replimune Group, Inc. (0001737953) (Issuer)
- INSIDERSEC Form 4 filed by Patel Sushil4 - Replimune Group, Inc. (0001737953) (Issuer)
- INSIDERSEC Form 4 filed by Dhingra Kapil4 - Replimune Group, Inc. (0001737953) (Issuer)
- INSIDERSEC Form 4 filed by Pucci Paolo4 - Replimune Group, Inc. (0001737953) (Issuer)
- INSIDERSEC Form 4 filed by Slattery Joseph P4 - Replimune Group, Inc. (0001737953) (Issuer)
- INSIDERSEC Form 4 filed by Hill Emily Luisa4 - Replimune Group, Inc. (0001737953) (Issuer)
- INSIDERSEC Form 4 filed by Peeples-Dyer Veleka4 - Replimune Group, Inc. (0001737953) (Issuer)
- INSIDERSEC Form 4 filed by Weinand Dieter4 - Replimune Group, Inc. (0001737953) (Issuer)
- INSIDERSEC Form 4 filed by Sarchi Christopher4 - Replimune Group, Inc. (0001737953) (Issuer)